[HTML][HTML] Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease
J Nowell, E Blunt, P Edison - Molecular Psychiatry, 2023 - nature.com
Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease
J Nowell, E Blunt, P Edison - Molecular psychiatry, 2023 - pubmed.ncbi.nlm.nih.gov
Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease
J Nowell, E Blunt, P Edison - Molecular Psychiatry, 2022 - orca.cardiff.ac.uk
Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
[PDF][PDF] Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease
J Nowell, E Blunt, P Edison - 2022 - scienovate.com
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common
neurodegenerative diseases [1]. AD is characterized by a progressive loss of cognitive …
neurodegenerative diseases [1]. AD is characterized by a progressive loss of cognitive …
Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.
J Nowell, E Blunt, P Edison - Molecular Psychiatry, 2022 - europepmc.org
Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
[HTML][HTML] Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease
J Nowell, E Blunt, P Edison - Molecular Psychiatry, 2023 - ncbi.nlm.nih.gov
Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.
J Nowell, E Blunt, P Edison - Molecular Psychiatry, 2022 - europepmc.org
Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …